Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Arbli TM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market. Arbli TM is a novel proprietary formulation of losartan, a proven therapy for treating ...

Arbli is designed for patients who require or prefer an oral liquid formulation of losartan. According to Scienture, the oral suspension provides a convenient and safe option, removing the ...

The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...